Sai Parenterals Limited Concludes 25th AGM; All Resolutions Passed
Sai Parenterals Limited held its 25th AGM on September 10, 2026. The meeting approved the financial statements for FY26, re-appointed key directors including MD Anil Kumar Karusala, and ratified several corporate actions. All 12 resolutions presented were passed.
The AGM outcomes, including director re-appointments and approval of financial statements and related party transactions, are significant for corporate governance and strategic direction.
The announcement details the successful conclusion of the AGM with all resolutions passed, indicating smooth governance and shareholder approval.
Sai Parenterals Limited held its 25th Annual General Meeting (AGM) on September 10, 2026, commencing at 11:14 AM IST and concluding at 12:05 PM IST, conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM).
During the meeting, chaired by Managing Director Mr. Anil Kumar Karusala, the company presented key financial highlights, significant milestones, and future outlook for the financial year 2026-27. Twelve resolutions were put forth for consideration.
These included the adoption of the Audited Balance Sheet, Statement of Profit & Loss, and Cash Flow Statement for the year ended March 31, 2026, along with the Auditors' and Directors' reports. The AGM also saw the re-appointment of Mr. Anil Kumar Karusala as Managing Director and Mrs. Vijitha Gorrepati as Whole-Time Director. Additionally, Mr. Kunal Kakumanu was appointed as an Executive Director. The appointment of M/s. Aakanksha Dubey & Co. as secretarial auditors for a term of five years was approved.
Further resolutions passed involved the variation in utilization of IPO proceeds and extension of time for their utilization, ratification of the Employee Stock Option Plan 2025 and its extension to subsidiary companies, approval of material related party transactions concerning loans to Sai Singapore Pte. Ltd. and transactions with Noumed Pharmaceuticals Pty. Limited, and ratification of remuneration to the Cost Auditor for FY 2026-27. All resolutions were passed with the requisite majority.
What to do with a filing like this
Sai Parenterals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sai Parenterals Limited. Read the original for the full detail.